Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise
This article was originally published in The Pink Sheet Daily
Executive Summary
The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.